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The clinical utility of renal concentrating capacity in polycystic kidney
disease. We studied 177 adult nonazotemic subjects with autosomal
dominant polycystic kidney disease (ADPKD) and 123 unaffected
family members (NADPKD). In order to assess the factors influencing
renal concentrating capacity maximal urinary osmolality (Uom) after
overnight water deprivation and vasopressin was measured. Uosm was
reduced in ADPKD (680 14) compared to NADPKD subjects (812
13 mOsm/kg). A greater severity of the architectural abnormality as
assessed by cyst number and size and remaining volume of normal
parenchyma was associated with a greater impairment of renal concen-
trating capacity. The concentrating defect was present in the youngest
ADPKD subjects and the rate of decline of concentrating capacity with
age in ADPKD paralleled that in NADPKD subjects. Based on the
initial 135 subjects studied, we developed an algorithm for diagnostic
screening for ADPKD utilizing blood pressure, serum creatinine and
Uosm designed to maximize sensitivity. When applied to a subsequent
population of 165 adults, 121 with ADPKD and 44 unaffected relatives,
this algorithm would have spared 20% of unaffected subjects from the
cost of ultrasound while failing to detect less than 2% of affected
subjects. This simple protocol thus offers a rapid and inexpensive way
to screen for ADPKD.
Autosomal dominant polycystic kidney disease (ADPKD) is
an important, frequent cause of chronic renal disease, account-
ing for 10 percent or more of end-stage renal failure [1, 2]. In
common with other causes of chronic renal failure, a defect in
the kidney's capacity to conserve water has been described in
subjects with ADPKD [3—6]. In general the renal concentrating
defect of chronic renal failure correlates with the degree of renal
insufficiency [7]. However, the presence of a vasopressin-
resistant renal concentrating defect has been observed in some
forms of renal disease including ADPKD prior to evidence of
deterioration of renal function [3—6, 8, 9]. In previous studies of
this phenomenon in ADPKD, glomerular filtration rate, age,
solute excretion and structural-functional correlations have not
been considered in relation to the early concentrating defect.
A defect in extracellular matrix in ADPKD might affect renal
epithelial transport or vasopressin-responsiveness, thus pro-
ducing a concentrating defect. On the other hand, structural
abnormalities in the polycystic kidney could affect the physics
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of the concentrating mechanism and produce a concentrating
defect. In order to assess these possibilities we measured
concentrating capacity in a large number of subjects with
ADPKD with normal renal function and in unaffected family
members and examined the correlation between concentrating
capacity and the renal structural abnormalities.
In addition we constructed and tested a screening algorithm
for ADPKD utilizing renal concentrating capacity.
Methods
Three hundred members of ADPKD families were studied.
All subjects underwent a detailed, formalized interview. The
subjects were 18 years to 70 years of age. They consumed meals
resembling their usual diets at home. Urinary frequency was
considered present if subjects stated that they urinated more
frequently than "normal"; polyuria if they made more urine
than what they considered to be normal; and nocturia if subjects
regularly awakened at night to void. Blood was obtained for
determination of serum sodium, potassium, calcium and creat-
mine. Urinalysis was performed to screen for glucosuria. Two
24-hour urine collections were obtained for creatinine, sodium,
potassium and urea. Creatinine clearances were normalized for
1.73 m2 body surface area.
The relationship between urinary concentrating capacity and
renal structural abnormalities was tested in the initial 193
subjects with serum creatinine less than or equal to 1.5 mg/dl
and not taking diuretics. All subjects had no fluid or solid intake
from 6:00 p.m. until 6:00 a.m. At 6:00 a.m. the subjects voided
and 5 units of aqueous vasopressin were administered subcuta-
neously. The next spontaneously voided urine was used for
determination of maximal urinary osmolality (Uosm).
A complete abdominal ultrasonogram was performed on all
subjects utilizing a high resolution real-time scanner (Acuson or
ATL with a 3.5 or 5 mHz transducer) and a conventional static
scanner (Picker 80L). Images from the static scan were used to
measure renal length and real-time examination was used to
determine the presence, number, location and size of renal
cysts in both longitudinal and transverse planes. All examina-
tions were made by one of three observers. The number of cysts
in each kidney estimated during real-time examination, the
predominant cyst size, and the extent of normal renal paren-
chyma were estimated according to the parameters listed in
Table 1. This approach, therefore, allowed a semiquantitative
675
676 Gabow et a!: Renal concentrating capacity in polycystic disease
Table 1. Architectural severity index components of
ultrasonographic abnormalities in ADPKD
Index Cyst Cyst
number number size Percent non-cystic parenchyma
0 0 0 100% (no cysts)
<6 <2 cm 76—99% (scattered cysts)
2 6—15 2—5 cm 25—75% (approx. equivalent
cystic and non-cystic
volume)
3 >15 >5 cm <25% (almost entirely cysts)
analysis of normal renal parenchyma. An estimate of renal
volume (RV) was determined for each kidney using the formula
for an ellipsoid with renal length (L), the anteroposterior
diameter (APD), and the width (W): RV 41T13 X (APDI4 + WI
4)2 x L12.
A renal architectural severity index was generated as the sum
of the scores assigned in each of three categories: cyst number,
predominant cyst size, and percent non-cystic parenchymal
volume of the more severely affected kidney (Table I). Utilizing
this method subjects without ADPKD would receive a severity
index of zero and the most severely affected ADPKD subjects
would receive a score of nine.
All laboratory determinations were performed by the Clinical
Research Center laboratory. Solute excretion was estimated
from the means of the two 24-hour urinary electrolyte and urea
excretions and calculated as (2[Na] + 2[K] + [urea]) x volume.
Data analyses were performed using SASIPC. Analysis of
covariance was used to compare linear regression lines. Anal-
ysis of variance (ANOVA) was used to compare the means of
multiple samples with specific a posterior! contrasts compared
using the Student-Newman-Keuls procedure. Multiple regres-
sion analysis was used to evaluate the linear relationships
between continuous independent variables and continuous de-
pendent variables. Logistic regression was used when the
dependent variable was dichotomous and the dependent varia-
bles were either discrete or continuous. When only two groups
were involved, comparison of the means was analyzed by the
Student's I-test and rates compared by the chi square test.
Variability among the data was reported as one standard error
about the mean. Statistical significance was determined by
statistical tests using a 0.05 level of significance.
Results
Rena! concentrating ability
Of the 193 family members who constitute this part of the
study, 106 were considered not to have ADPKD (NADPKD)
based on the complete absence of renal cysts on ultrasonogra-
phy, whereas 87 individuals had ADPKD on the basis of
bilateral renal cysts totalling five or more by ultrasonography.
The mean ages (35 1 vs. 38 1 years), serum creatinine
concentrations (0.98 0.02 vs. 1.00 0.02 mgldl) and creati-
nine clearances (100 3 vs. 102 3 mllminll .73 m2) were
similar in ADPKD and NADPKD groups (Table 2).
Symptoms of polyuria (7% vs. 14%), nocturia (32% vs. 27%)
and urinary frequency (31% vs. 30%) did not differ between the
ADPKD and the NADPKD subjects. The mean 24-hour urine
volumes were also similar in ADPKD subjects and NADPKD
subjects (1.97 0.08 vs. 1.90 0.07 liters). All subjects in both
groups had normal serum sodium, potassium and calcium
concentrations. None had glucosuria.
Despite similar age and renal function, the mean maximal
urinary osmolality was significantly lower in the ADPKD group
as compared to the NADPKD subjects (680 14 vs. 812 13
mOsmlkg, P < 0.0001; Table 2). This difference is not explained
by a difference in solute load because 24-hour solute excretions
were similar in the two groups (Table 2). The Uosm had
biologically insignificant correlations with creatinine clearance
(r = 0.20) and solute excretion (r = 0.23) in the NADPKD
population and solute excretion (r = 0.15) in the ADPKD
population. A weak correlation existed between Uosm and
creatinine clearance in the ADPKD group (r = 0.38, P C
0.0003). In both the ADPKD and NADPKD groups the Uosm
was inversely related to age, but at any given age the Uosm was
significantly lower in the ADPKD subjects (Fig. I). For exam-
ple, in the 18 to 28 year old age groups, ADPKD subjects had
mean Uosm of779 30 in contrast to the NADPKD group with
mean Uosm of 893 23 mOsmlkg (P <0.004). The slopes of the
linear relationships between Uøsm and age were similar for both
ADPKD (—6.27), and NADPKD (—6.26 mOsmlkglyr), demon-
strating similar decrements in renal concentrating capacity in
both groups with age.
The relationship of the defect in urinary osmolality to the
altered renal architecture in the ADPKD subjects was assessed.
A significant inverse relationship between maximal Uosm and
mean renal volume was present (Fig. 2), Despite similar normal
renal function, subjects with larger kidneys had a more severe
defect in renal concentrating capacity. Cyst number was also
related to concentrating capacity. ADPKD subjects with more
than 15 cystslkidney had a significantly lower maximal Uosm
than subjects with 6 to 15 cystslkidney (647 18 vs. 733 17
mOsmlkg, P C 0.004). Cyst size was not related directly to
maximal Uosm, but the percentage of non-cystic parenchyma
was (P C 0.0001).
The renal architecture severity index demonstrated a highly
significant linear relationship with maximal Uosm (P C 0.0001,
Fig. 3). This relationship remained significant after adjustment
for age and creatinine clearance (C) using multiple regression
(maximal Uosm = 847 — 26 x index — 4 x age — 1.4 x Ccr; P
C 0.004 for the index). However, there was no significant
relationship between creatinine clearance or age and renal
severity index.
C!inica! algorithm
We developed a screening construct for ADPKD incorporat-
ing the maximal Uosm as suggested by Chester, et al [6]. We
reasoned that the clinician confronted with members of an
ADPKD family should refer individuals with hypertension or
azotemia for more definitive evaluation such as ultrasonogra-
phy. We developed this screening from the first 135 subjects.
Sixty-three were hypertensive and none were azotemic. We
then applied logistic regression analysis to develop a formula
which provided a value for maximal Uosm for any age in adults
without hypertension or azotemia that allowed the best sensi-
tivity for including subjects with ADPKD in the true positive
result group.
This analysis yielded the formula: maximal Uosm (mOsmlkg)
= 1086 — 8.3 x age (yrs). A Uosm that is less than the calculated
value from this formula is considered a positive result, indicat-
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Table 2. Characteristics of NADPKD and ADPKD subjects
Group N Age yrs
Serum
creatinine
ing/di
Creatinine
clearance
m!/min/l.73 m2
Solute
excretion
mOsmI24 hr
Um
mOsm/kg
NADPKD 106 38 1 0.98 0.02 102 3 850 21 812 13
ADPKD 87 35 1 1.00 0.02 100 3 833 24 680 14
1200
1000
8000
E
0
aC
600
>-
a0
E00
aC
Fig. 2. The correlation between mean renal
1500 volume and maximal urinary osmolality inADPKD subjects. This inverse relationship is
significant (r = —0.50, P < 0.001).
ing the need for more definitive testing for ADPKD. A U0sm
greater then the calculated value is considered a negative result,
indicating no need for immediate further evaluation. Forty-two
of the 72 subjects had a positive U0sm screening test; 20 had
ADPKD by ultrasonography (48%). Only one of the 30 subjects
with a negative U0sm test had ADPKD (3%) (Fig. 4).
To validate this three-step screening construct utilizing blood
pressure, serum creatinine and maximal Uøsm, we applied the
jackknife procedure which is a powerful tool for estimating the
true misclassification rate as opposed to the observed misclas-
sification rate in this group of 135 subjects [10]. This test yielded
a false negative rate of 3.0 percent (3% of ADPKD subjects
missed) and a true negative rate of 37.5% (37.5% of NADPKD
subjects spared the need for ultrasonography).
Significant difference at the P < 0.0001 level.
0
0 0 0
00
000
000 0 0•0
0
0•-.
0
400
20 40
Age, years
60
Fig. 1. The correlation between age and
maximal urinary osmolality in ADPKD
(closed circles) and NADPKD .cubjects (open
circles). The relationships are significant for
both the ADPKD (r =
—0.40, P < 0.0001) and
80 the NADPKD groups (r = —0.66, P <0.0001). The intercepts of the lines differ (P <
0.02), but the slopes do not.
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Fig. 3. The correlation between renal architectural severity index and
maximal urinary osmolality. The inverse relationship is significant (r =
—0.46, P < 0.0001). The relationship holds after adjusting for CCr and
age, P < 0,004; N indicated in parentheses.
We then applied this algorithm prospectively to an indepen-
dent population comprised of the next 165 subjects at risk for
ADPKD. The results are displayed in Figure 5. Only two of 121
subjects with ADPKD would not have been recommended for
ultrasonography, a false negative rate of less than 2%. Twenty
percent of subjects with NADPKD would have been spared
ultrasonography.
Since the prevalence of ADPKD in our initial and prospective
groups differ from what would be expected in a screening
population (approximately 50%), predictive value may be a
more appropriate indicator of clinical utility than sensitivity.
Combining the initial and prospective groups, the predictive
value of a negative test is estimated to be 93%. In other words,
a clinician can be confident that 93% of the individuals who test
negative by this algorithm in fact do not have ADPKD.
Discussion
The ability of the normal human kidneys to concentrate the
final urine is considerable, generally achieving a maximal U0m
in excess of 800 to 1000 mOsm/kg H20. This renal concentrat-
ing capacity as estimated by maximal Usm is a sensitive
indicator of renal functional impairment and correlates well
with the degree of renal insufficiency [71.
The present study demonstrates that individuals with
ADPKD may develop a renal concentrating defect before
glomerular filtration rate (GFR) decreases. Four previous stud-
ies have described a vasopressin-resistant concentrating defect
in a total of 54 subjects with ADPKD [3—6]. GFR ranged from
4.5 to 165 mI/mm. Twenty-three subjects had either other
disorders known to affect renal concentrating capacity or
advanced renal insufficiency. Moreover, the effect of age on
concentrating capacity was not considered.
This study reveals that the defect in renal concentrating
capacity is present in ADPKD subjects when compared to
non-affected family members of similar age, renal function and
solute excretion. As anticipated, Uom decreased significantly
with increasing age, but at similar rates in ADPKD and
NADPKD subjects (Fig. 1).
The renal concentrating defect observed in ADPKD subjects
closely paralleled the severity of anatomical changes caused by
Yes r US
OADPKD
0 NADPKD
Yes
20 ADPKD
22 NADPKD
1 ADPKD No
29 NADPKD
FIg. 4. An algorithm developed from a population of 56 ADPKD and
79 NADPKD subjects. The decision points are diamonds. US repre-
sents ultrasound of the kidneys. The number of subjects identified at
each decision point is listed. The U0,,, cutoff is the minimum value for
maximal Uøsm described by the formula given in the text to maximize
sensitivity.
the renal cysts independent of age and GFR. This finding
suggests that anatomical disruption of the renal concentrating
mechanism is responsible, at least in part, for the early appear-
ance of a concentrating defect in ADPKD. An important site of
cyst formation appears to be the collecting duct at the cortico-
medullary junction [4]. Thus, the more cysts present in a
kidney, the more likely it is that the medullary architecture and
countercurrent mechanisms that are vital in producing a maxi-
mally concentrated urine are distributed.
On the other hand, animals given the cystogenic chemical
2-amino-4,5-diphenyl-thiazole (DPT) develop a defect in renal
concentrating capacity early in the course of the injury when
the only morphologic changes are hyperplasia and tubular
dilatation [11]. Moreover, in tissue culture, cells derived from
cysts of human kidney of individuals with ADPKD fail to
demonstrate the normal cyclic adenosine monophosphate re-
sponse to vasopressin which is seen in cells from tubules of
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Fig. 5. Application of the algorithm to a prospective group of /65
subjects, 121 ADPKD and 44 NADPKD. See Fig. 4 for details.
normal kidneys [12]. These studies suggest that a vasopressin-
resistant defect in renal concentration in ADPKD may occur
independently of a direct gross structural alteration. This pos-
sibility is not inconsistent with the observations in the present
study of a concentrating defect observed in the youngest adults
and a similar rate of decrease in maximal Usmin ADPKD and
NADPKD subjects with aging.
Given the presence of this early concentrating defect, we
were interested in assessing if a simple screening protocol could
be useful in identifying members of ADPKD families who
should undergo renal ultrasonography, with the goals to mini-
mize failure to detect ADPKD and to decrease the number of
unaffected family members who would be sent for ultrasonog-
raphy. Using the natural progression of an office evaluation,
individuals with treated (history) or detectable (physical exam-
ination) hypertension are assigned to undergo ultrasonography.
The progression to ultrasonography at this point reflects that 56
percent of the hypertensive individuals in our initial study group
had ADPKD. The remaining individuals then have serum
creatinine determined. Those with azotemia of any degree (Se.
> 1.5 mg/dl) undergo ultrasonography. This step is included to
emphasize to clinicians that any individual in an ADPKD family
with an elevated creatinine should undergo ultrasonography.
The remaining individuals return for a maximal urinary concen-
tration screening test. Those who fail to achieve the predicted
value undergo ultrasonography. This overall scheme utilized in
the initial study population and the prospective population
taken together failed to identify 1.7% percent of affected
individuals (3 of 177) and would have abrogated the need for
ultrasonography in 30% of unaffected family members (38 of
123). In view of the 600,000 Americans affected by ADPKD, the
cost savings of the screening approach are substantial. In our
institution the cost of the vasopressin, serum creatinine and
urine osmolality measurements is about $50 in contrast to $300
for renal ultrasonography. Thus, the screening approach is
much less expensive. The entire scheme yields a sensitivity of
98 percent and a specificity between 20 and 37 percent. Since
this screen is not 100 percent sensitive, the clinician must
realize that some ADPKD subjects would be classified as
negative falsely. Moreover, even ultrasonography can yield
false negative results particularly in individuals less than 20
years old. Thus, in the young, serial studies may be necessary
or if there is an immediate need for more sensitive diagnostic
testing, computed tomography with contrast or gene linkage
testing could be utilized. With this caveat, the screening proto-
col appears reasonable.
In summary, the present study demonstrates a defect in renal
concentrating capacity in ADPKD that antedates impairment in
GFR. The close correlation between the severity of the con-
centrating defect and the severity of the anatomic changes
suggests a role for anatomic disruption of the vasculotubular
architecture, but the data also allow the possibility that vaso-
pressin responsiveness may be important. The concentrating
defect in early ADPKD allows construction of a simple screen-
ing algorithm using blood pressure, serum creatinine and con-
centrating capacity. This inexpensive protocol has promise for
reducing the cost of screening for ADPKD.
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